Binds Bacterium Or Similar Microorganism Or Component Or Product Thereof (e.g., Pseudomonas, Chlamydia, Clostridium, Bacterium-associated Antigen, Etc.) Patents (Class 530/389.5)
-
Patent number: 7569677Abstract: A composition including a purified antibody conjugated with at least one antibiotic, the antibody having an antigen-binding portion that binds at least one antigen derived from Staphylococcus or Streptococcus.Type: GrantFiled: June 27, 2002Date of Patent: August 4, 2009Assignee: STROX Biopharmaceuticals, LLCInventor: Stanley A. Kim
-
Patent number: 7563874Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: GrantFiled: August 1, 2003Date of Patent: July 21, 2009Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Peter Amersdorfer
-
Patent number: 7560109Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The use of antibodies against Fusobacterium necrophorum adherence antigens decreases the colonization of F. necrophorum sufficiently to reduce or eliminate the incidence of liver abscesses in the animals.Type: GrantFiled: July 12, 2007Date of Patent: July 14, 2009Assignee: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness
-
Patent number: 7557194Abstract: The present invention provides nucleic acid and amino acid sequence of the novel I-1 and I-2 polypeptides, which are associated with human inflammatory bowel disease (IBD). Methods of diagnosing and treating inflammatory bowel disease using the IBD-associated I-1 and I-2 antigens also are provided.Type: GrantFiled: April 30, 2004Date of Patent: July 7, 2009Assignee: The Regents of the University of CaliforniaInventors: Jonathan Braun, Christopher Sutton
-
Publication number: 20090162379Abstract: Provided herein is a method for identifying small molecule inhibitors of S. aureus SdrD protein attachment to a host cell receptor using a structural model of SdrD protein-receptor interaction. Also provided are the small molecule inhibitors so identified and synthetic small molecules effective to bind SdrD protein and/or the host cell receptor. In addition, antibodies directed against SdrD protein are provided. Further provided are methods of treating or preventing S. aureus associated lung infections and of inhibiting S. aureus adherence to a lung cell using the small molecules and antibodies described herein.Type: ApplicationFiled: October 1, 2008Publication date: June 25, 2009Inventors: Magnus Hook, Elena M. Barbu
-
Publication number: 20090087863Abstract: Disclosed is a novel Lepidopteran- and Coleopteran-active ?-endotoxin polypeptide, and compositions comprising the polypeptide, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that comprise nucleic acid segments encoding the polypeptide. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising the novel sequences of the invention, as well as methods for controlling an insect population, such as the Western Corn Rootworm and Colorado potato beetle, and for conferring to a plant population resistance to the target insect species.Type: ApplicationFiled: September 29, 2008Publication date: April 2, 2009Inventors: Anne-Marie Light Mettus, James A. Baum
-
Publication number: 20090074755Abstract: The present invention relates to compositions and methods for treating Staphylococcus aureus (S. aureus) infections. In particular, the present invention provides vaccines comprising a Panton-Valentine Leukocidin (u) antigen, antibodies which bind a PVL antigen and compositions containing the same, methods of making such compositions and methods for treating S. aureus infections, including those that are community acquired methicillin-resistant infections. The present invention also provides PVL antibodies, including PVL antibodies specific for a single PVL subunit, and PVL antigens, including conjugated and mutated PVL antigens.Type: ApplicationFiled: June 13, 2006Publication date: March 19, 2009Inventors: Kimberly Louise Taylor, Ali Ibrahim Fattom
-
Publication number: 20090053292Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.Type: ApplicationFiled: December 21, 2007Publication date: February 26, 2009Inventors: Kenneth Tucker, Ulrich F. Tillmann
-
Publication number: 20090041782Abstract: A polynucleotide encoding a polypeptide which lowers the glucose side chain amount in a serotype-specific polysaccharide antigen of Streptococcus mutans; novel Streptococcus mutans strain having the above polynucleotide; an antibody specific to this Streptococcus mutans strain; and a method of detecting the above-described Streptococcus mutans strain occurring in a subject sample. According to this method, it is possible to examine the presence or absence of Streptococcus mutans of an untypable serotype in a subject sample to thereby specify a subject having a high risk of the onset of infective endocarditis.Type: ApplicationFiled: December 28, 2004Publication date: February 12, 2009Inventors: Takashi Ooshima, Kazuhiko Nakano
-
Publication number: 20090011442Abstract: The present invention relates to isolation and identification of novel M. tuberculosis excretory secretory antigen proteins released in vitro/in vivo, raising the specific immunoglobulins and their use as diagnostic reagents for tuberculosis. The invention further relates to a combination of antigens and immunoglobulins for effective detection and immunomonitoring of pulmonary or extrapulmonary Mycobacterium tuberculosis in children and adults by different immunological methods. The invention also relates to detection of tuberculosis with HIV coinfection. Further the invention also shows potential of mycobacterial metallo serine protease (SEVA TB ES-31 antigen) as drug target for screening potential antitubercular drugs.Type: ApplicationFiled: January 16, 2008Publication date: January 8, 2009Inventor: Harinath C. Bhaskar
-
Publication number: 20090010928Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.Type: ApplicationFiled: September 28, 2007Publication date: January 8, 2009Applicant: ELUSYS THERAPEUTICS, INC.Inventor: Leslie S. Casey
-
Publication number: 20080299153Abstract: The present invention pertains to the discovery that B. anthracis possesses a luxS gene that encodes a functional LuxS polypeptide, and that B. anthracis synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant B. anthracis bacteria lacking the function of the luxS gene, which do not produce a functional AI-2 molecule and have growth defects compared to wild-type B. anthracis. The invention also concerns methods for inhibiting the growth of B. anthracis, or for preventing or treating B. anthracis infection, by inhibiting the activity of the B. anthracis LuxS polypeptide, or by exposure of the B. anthracis to furanone. In particular, the invention concerns the use of furanone, a compound that inhibits AI-2-mediated quorum-sensing, to inhibit the growth of B. anthracis, to inhibit B. anthracis toxin production, particularly that of protective antigen, and to prevent or treat B. anthracis infection. The invention also provides methods to prevent B.Type: ApplicationFiled: March 7, 2008Publication date: December 4, 2008Applicants: NEW YORK UNIVERSITY, UNIVERSITY OF CONNECTICUTInventors: Marcus B. Jones, Martin J. Blaser, Thomas Wood, Dacheng Ren
-
Patent number: 7442373Abstract: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided.Type: GrantFiled: January 24, 2005Date of Patent: October 28, 2008Assignee: Emergent Product Development Gaithersburg Inc.Inventors: Jeanne Morrow, legal representative, Angray S. Kang, Fei Wang, Ivy Jiang, Ritsuko Sawada, Wolfgang Scholz, Phillip R. Morrow
-
Publication number: 20080241191Abstract: Disclosed is a cell wall C-polysaccharide antigen of Streptococcus pneumoniae which contains not more than 10% by weight of protein, and preferably less which has been purified with 0.1N NaOH prior to deproteinizing. Also disclosed are polyvalent antibodies raised against Streptococcus pneumoniae which have been affinity purified by passing them over a chromatographic affinity matrix to which is coupled the purified and at least partially deproteinized antigen to render them antigen-specific.Type: ApplicationFiled: October 31, 2007Publication date: October 2, 2008Applicant: Binax, Inc.Inventors: Norman James Moore, Mary Kathleen Fent, Vladimir Andrei Koulchin, Elena Valentin Molokova
-
Publication number: 20080241104Abstract: Disclosed are EspFU (EspF-like polypeptide encoded by a gene of the cryptic prophage CP-933U of enterohemorrhagic E. coli) polypeptides, fragments thereof, nucleic acids that encode EspFU polypeptides, or fragments thereof, and cells including the polypeptides, fragments, and/or nucleic acids. Also disclosed are model systems, kits, and methods for screening that use, for example, EspFU polypeptides and nucleic acids. Also included are pharmaceutical and diagnostic compositions and methods of diagnosis and treatment of EHEC infections.Type: ApplicationFiled: July 24, 2007Publication date: October 2, 2008Applicant: UNIVERSITY OF MASSACHUSETTSInventors: John M. Leong, Kenneth G. Campellone
-
Publication number: 20080213285Abstract: The present invention relates to secreted Chlamydia polypeptides, which may be expressed by a Gram-negative bacterial strain and secreted by the type III secretion pathway of said bacterial strain. The present invention also relates to polynucleotides coding for these polypeptides, as well as to the therapeutic and vaccination uses of these secreted Chlamydia polypeptides.Type: ApplicationFiled: October 23, 2007Publication date: September 4, 2008Applicant: INSTITUT PASTEURInventors: Agathe SUBTIL-SANDS, Alice DAUTRY-VARSAT
-
Publication number: 20080025993Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: August 28, 2003Publication date: January 31, 2008Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 7279171Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.Type: GrantFiled: August 11, 2003Date of Patent: October 9, 2007Assignee: Board of Supervisors of Louisiana State University and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
-
Patent number: 7256270Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals.Type: GrantFiled: January 7, 2002Date of Patent: August 14, 2007Assignee: Camas, IncorporatedInventors: Peter Nash, Donald L. Robinson, legal representative, John W. Rosevear, deceased
-
Patent number: 7256269Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals.Type: GrantFiled: December 26, 2001Date of Patent: August 14, 2007Assignee: Camas, IncorporatedInventors: Peter Nash, D. L. Robinson, legal representative, Donald L. Robinson, John W. Rosevear, deceased
-
Patent number: 7241443Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tract of host food animals. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, drying the egg contents and adding to the feed or water for the host animals. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody is used to promote the growth of food animals by improving feed conversion rates by decreasing the waste of dietary protein caused by the presence of certain colony-forming organisms in the animals, and to substantially reduce or eliminate the incidence of illnesses caused by the presence of certain illness-causing colony-forming immunogens, such as E.Type: GrantFiled: July 14, 2000Date of Patent: July 10, 2007Assignee: Camas IncorporatedInventors: Peter Nash, Donald L. Robinson, legal representative, John W. Rosevear, deceased
-
Patent number: 7235644Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: March 15, 2006Date of Patent: June 26, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 7230087Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: June 29, 2005Date of Patent: June 12, 2007Assignees: Beth Israel Deaconess Medical Center, Inc., Brigham & Women's Hospital, Inc.Inventors: Gerald B. Pier, Michael J. Preston, Lisa Cavacini, Marshall R. Posner
-
Patent number: 7220423Abstract: Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of Chlamydia, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.Type: GrantFiled: October 15, 2004Date of Patent: May 22, 2007Assignee: University of ManitobaInventor: Robert C. Brunham
-
Patent number: 7160990Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: GrantFiled: March 23, 2004Date of Patent: January 9, 2007Assignee: Biostapro ABInventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Patent number: 6967240Abstract: The present invention relates to a protienaceous compound or functionally active derivative or part thereof having a binding site for a group represented by formula (I) which is part of a group of toxins derived from various cyanobacteria, to a method for its production, to diagnostic kits and to an affinty matrix (e.g. for use in immunoaffinity columns, online detection and purifications devices) containing the proteinaceous compound as well as to methods for substantially decreasing the amount of a compound containing the group represented by formula (I) in fluids or for concentrating compounds, e.g. toxins, containing the group represented by formula (I) from fluids such as crude water samples, extracts of algae or other tissue samples, e.g. to determine toxin concentrations.Type: GrantFiled: September 6, 2000Date of Patent: November 22, 2005Assignees: The Regent of the University of California, New Zealand Agricultural Research Institute LimitedInventors: Daniel R. Dietrich, Werner Fischer, A. Richard Chamberlin, James B. Aggen, Ian Garthwaite, Christopher O. Miles, Kathryn M. Ross, Neale R. Towers
-
Patent number: 6951925Abstract: The invention relates to agents and processes for detecting bacteria of the genus Listeria, in particular L. monocytogenes. The agents according to the invention include primers whose sequence is selected from the iap gene of L. monocytogenes. In addition, the agents according to the invention include peptides whose sequence is selected from the p60 protein and which are suitable for producing specific antibodies for the immunological detection of L. monocytogenes.Type: GrantFiled: August 11, 1999Date of Patent: October 4, 2005Assignee: Merck Patent Gesellschaft mit beschrankterInventors: Peter Schubert, Siegfried Neumann, Martina Pawelzik, Winfried Linxweiler, Christa Burger, Andreas Bubert, Werner Goebel, Stefan Köhler
-
Patent number: 6913756Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.Type: GrantFiled: April 29, 1998Date of Patent: July 5, 2005Assignee: The UAB Research FoundationInventor: John F. Kearney
-
Patent number: 6881410Abstract: The present invention provides bacterial and fungal ABC transporter proteins, immunogenic fragments thereof, neutralising agents specific thereto and binding agents specific thereto for therapeutic and diagnostic use, together with diagnostic test methods, methods of same and kits for performing same. Also provided are immunodominant conserved antigens from gram positive staphylococci, together with neutralising and binding agents specific thereto for use in therapy and diagnosis, and methods of same. Also provided are Staphylococcal holomogues of IstA and IstB and immunogenic fragments thereof, and their uses in methods of treatment and diagnosis of the human or animal body.Type: GrantFiled: January 25, 2002Date of Patent: April 19, 2005Assignee: Neu Tec Pharma PLCInventors: James Peter Burnie, Ruth Christine Matthews
-
Patent number: 6855513Abstract: The invention provides methods for identifying a modulator of quorum sensing signaling in bacteria, and for identifying a quorum sensing controlled gene in bacteria. In addition, the invention provides quorum sensing controlled genetic loci in Pseudomas aeruginosa. Novel indicator strains and vectors for engineering the strains for use in the method of the invention are also provided.Type: GrantFiled: September 1, 2000Date of Patent: February 15, 2005Assignees: University of Iowa Research Foundation, Vertex Pharmaceuticals (San Diego) LLCInventors: Marvin Whiteley, Kimberly M. Lee, E. Peter Greenberg, Ute Muh
-
Patent number: 6838552Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Type: GrantFiled: November 8, 2000Date of Patent: January 4, 2005Assignee: Vanderbilt UniversityInventors: William M. Mitchell, Charles W. Stratton
-
Patent number: 6838085Abstract: Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of Chlamydia, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.Type: GrantFiled: January 7, 2002Date of Patent: January 4, 2005Assignee: University of ManitobaInventor: Robert C. Brunham
-
Patent number: 6824992Abstract: The present invention relates to a histidine kinase, two-component gene (CaHK1) from Candida albicans. CaHK1 encodes a 2471 amino acid protein with an estimated molecular mass of 281.8 kDa. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates agonists and antagonists and to screening methods for identifying agonists and antagonists of CaHK1 polypeptide activity. The invention additionally relates to diagnostic methods for detecting CaHK1 nucleic acids, polypeptides, and antibodies in a biological sample. The present invention further relates to novel antagonists and vaccines for the prevention or attenuation of infection by Candida albicans.Type: GrantFiled: April 5, 2002Date of Patent: November 30, 2004Assignees: Human Genome Sciences, Inc., The Georgetown UniversityInventors: Antonio Jose C. Abad, Gil H. Choi, Richard A. Calderone
-
Patent number: 6713059Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.Type: GrantFiled: April 11, 2002Date of Patent: March 30, 2004Assignee: University of RochesterInventors: Andrew S. Kende, Barbara H. Iglewski, Roger Smith, Richard P. Phipps, James P. Pearson
-
Patent number: 6686452Abstract: Disclosed is a novel &dgr;-endotoxin, designated CryET29, that exhibits insecticidal activity against siphonapteran insects, including larvae of the cat flea (Ctenocephalides felis), as well as against coleopteran insects, including the southern corn rootworm (Diabrotica undecimpunctata), western corn rootworm (D. virgifera), Colorado potato beetle (Leptinotarsa decemlineata), Japanese beetle (Popillia japonica), and red flour beetle (Tribolium castaneum). Also disclosed are nucleic acid segments encoding CryET29, recombinant vectors, host cells, and transgenic plants comprising a cryET29 DNA segment. Methods for making and using the disclosed protein and nucleic acid segments are disclosed as well as assays and diagnostic kits for detecting cryET29 and CryET29 sequences in vivo and in vitro.Type: GrantFiled: March 12, 2003Date of Patent: February 3, 2004Assignee: Monsanto Technology LLCInventors: Mark J. Rupar, William P. Donovan, Yuping Tan, Annette C. Slaney
-
Patent number: 6680168Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: GrantFiled: March 22, 2001Date of Patent: January 20, 2004Assignee: Acambis, Inc.Inventors: William D. Thomas, Jr., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Publication number: 20030235903Abstract: The invention provides an improved method of propagating Cryptosporidium in cell culture. The methods supports the complete life cycle or Cryptosporidium and produces all known forms of the parasite in addition to two novel forms. Cryptosporidium parasites propagated in vitro can be used to produce a vaccine composition for immunizing animals against Cryptosporidium infection.Type: ApplicationFiled: June 20, 2002Publication date: December 25, 2003Applicants: University Technologies International, Inc., Murdoch UniversityInventors: R. C. Andrew Thompson, Nawal S. Hijjawi, Manual Campos, Amber Appelbee, Merle E. Olson
-
Patent number: 6667035Abstract: The invention relates to monoclonal antibodies capable of recognizing and neutralizing epitopes from the ligand domain, the translocation domain or the catalytic domain of the enterotoxin (toxin A) and cytotoxin (toxin B) from Clostridium difficile, as well as their production and therapeutical and prophylactic applications to diseases due to the toxins.Type: GrantFiled: March 27, 2000Date of Patent: December 23, 2003Inventors: Christoph Von Eichel-Streiber, Michael Moos
-
Patent number: 6635434Abstract: A hapten-polymer carrier complex was found to be useful for immunoassay purposes, specifically ELISAs, for the detection of pesticides and their degradation products in hydrosoil and ground water. The degradation products of Casoron G® (also known as dichlorobenzonitrile and dichlorbenil) and Prefix® (also known as chlorthiamid and dichlorobenzthiamide) are analytes detected with high specificity and sensitivity, particularly the degradation product BAM (2,6-dichlorobenzamide). The polymer carrier complex is bound to the hapten via a linker unit, strategically positioned meta to the amide or amide derivative of BAM.Type: GrantFiled: July 21, 2000Date of Patent: October 21, 2003Assignee: Exiqon A/SInventors: Mogens Havsteen Jakobsen, Leif Bruun, Brian Pedersen
-
Patent number: 6607730Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an POMP91B precursor protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the POMP91B precursor gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 29, 1999Date of Patent: August 19, 2003Assignee: Aventis Pasteur Limited/Aventis Pasteur LimiteeInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6605287Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.Type: GrantFiled: August 28, 1998Date of Patent: August 12, 2003Assignee: Board of Supervisors of Louisiana State University & Agricultural and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
-
Patent number: 6544516Abstract: The present invention provides bacterial and fungal ABC transporter proteins, immunogenic fragments thereof, neutralizing agents specific thereto and binding agents specific thereto for therapeutic and diagnostic use, together with diagnostic test methods, methods of same and kits for performing same. Also provided are immunodominant conserved antigens from gram positive staphylococci, together with neutralising and binding agents specific thereto for use in therapy and diagnosis, and methods of same. Also provided are Staphylococcal homologues of IstA and IstB and immunogenic fragment thereof, and their uses in methods of treatment and diagnosis of the human or animal body.Type: GrantFiled: January 4, 1999Date of Patent: April 8, 2003Assignee: NeuTec Pharma plcInventors: James Peter Burnie, Ruth Christine Matthews
-
Patent number: 6537550Abstract: The present invention relates to use of avian antibodies and/or antigen binding fragments thereof, for the production of a drug for treatment and/or prevention of respiratory tract infection. The drug is administered through local application at the oral cavity and/or pharynx.Type: GrantFiled: September 20, 1999Date of Patent: March 25, 2003Assignee: Immun System I.M.S. ABInventors: Anders Larsson, Hans Kollberg
-
Patent number: 6528061Abstract: A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a pathogenic microorganism of bacterial, viral, or fungal origin. The polypeptide is capable of inducing an immune response in vivo against the pathogenic microorganism. The immune response confers protection in mice against challenge with the virulent microorganisms.Type: GrantFiled: August 31, 1998Date of Patent: March 4, 2003Inventors: Armelle Phalipon, Philippe Sansonetti, Franco Felici, Riccardo Cortese, Jean Pierre Kraehenbuhl
-
Patent number: 6488929Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to the infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: GrantFiled: July 12, 1999Date of Patent: December 3, 2002Assignee: Montana State UniversityInventors: Jim E. Cutler, Yongmoon Han
-
Patent number: 6458933Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.Type: GrantFiled: May 19, 1999Date of Patent: October 1, 2002Assignee: Immunomedics, Inc.Inventor: Hans J. Hansen
-
Patent number: 6429189Abstract: Pharmaceutical applications of a chemodenervating agent reduce pain by altering release of pain and inflammation-mediating autocoids, with a duration of action between 12-24 weeks. The limiting factor in dosing for this application is weakness and paralysis created by higher doses of the chemodenervating pharmaceutical. This weakness and paralysis is mediated by action of the neurotoxin component of the chemodenervating pharmaceutical. The invention described herein represents a novel mechanism and pharmaceutical formulation which eliminates the neurotoxin component of the chemodenervating pharmaceutical, while retaining the cytotoxin component which provides an essential bioeffect for the relief of pain and inflammation. The invention allows for improvement in administering the pharmaceutical agent for the reduction of pain and/or inflammation without causing muscular weakness and paralysis.Type: GrantFiled: December 10, 1999Date of Patent: August 6, 2002Assignee: Botulinum Toxin Research Associates, Inc.Inventor: Gary E. Borodic
-
Patent number: 6403090Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.Type: GrantFiled: June 17, 1999Date of Patent: June 11, 2002Assignee: The Research and Development Institute Inc.Inventors: Jim E. Cutler, Yongmoon Han
-
Patent number: 6376658Abstract: The present invention relates to a protein related to encapsulation in immune reaction and a gene encoding the same.Type: GrantFiled: March 9, 2000Date of Patent: April 23, 2002Assignee: Samyang Genex CorporationInventors: Bok Luel Lee, Mi Young Cho, Chong Jin Park, Seung-Suh Hong, Hyun-Soo Lee
-
Patent number: 6350449Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies to these conjugate vaccines. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 1999Date of Patent: February 26, 2002Assignee: Baxter International Inc.Inventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon